Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.37 |
| ▸ | FYN | P06241 | 3/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.35 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.35 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12985623 | 0.90 | PIK3CA (0.42) | TNFPIK3CADYRK1APIK3CDPIK3CB | |
| SCHEMBL3517518 | 0.86 | TNF (0.47) | TNFPIK3CADYRK1APIK3CDPIK3CB | |
| SCHEMBL12986347 | 0.85 | TNF (0.43) | TNFPIK3CADYRK1APIK3CDPIK3CB | |
| SCHEMBL12985818 | 0.85 | TNF (0.47) | TNFPIK3CADYRK1APIK3CDPIK3CB | |
| SCHEMBL12986314 | 0.84 | TNF (0.46) | TNFPIK3CADYRK1APIK3CDPIK3CB | |
| SCHEMBL3517515 | 0.82 | TNF (0.49) | TNFPIK3CADYRK1APIK3CDPIK3CB | |
| SCHEMBL12985887 | 0.81 | TNF (0.48) | TNFPIK3CADYRK1APIK3CDPIK3CB | |
| SCHEMBL12986612 | 0.80 | TNF (0.47) | TNFPIK3CADYRK1APIK3CDPIK3CB | |
| SCHEMBL12986043 | 0.80 | TNF (0.46) | TNFPIK3CADYRK1APIK3CDPIK3CB | |
| SCHEMBL3514694 | 0.80 | PIK3CA (0.47) | TNFPIK3CADYRK1APIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | CAPRARO HANS-GEORG | 2010-12-09 | — | — | US | disclosed |
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | CAPRARO HANS-GEORG | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | PI4KA, PIP5K1B, PIP4K2A | TNF 1981/4885PIK3CA 10/4885DYRK1A 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.